Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial

详细信息	查看全文 | 推荐本文 |

• 作者：Dr Tohru Kobayashi ; MD^a ; ^{torukoba@nifty.com} ; Prof Tsutomu Saji ; MD^b ; Tetsuya Otani ; MD^c ; Prof Kazuo Takeuchi ; MPH^d ; Tetsuya Nakamura ; MD^e ; Prof Hirokazu Arakawa ; MD^a ; Taichi Kato ; MD^f ; Prof Toshiro Hara ; MD^g ; Prof Kenji Hamaoka ; MD^h ; Prof Shunichi Ogawa ; MDⁱ ; Masaru Miura ; MD^j ; Yuichi Nomura ; MD^k ; Shigeto Fuse ; MD^l ; Prof Fukiko Ichida ; MD^m ; Mitsuru Seki ; MDⁿ ; Ryuji Fukazawa ; MDⁱ ; ^o ; Chitose Ogawa ; MD^p ; Kenji Furuno ; MD^q ; Hirohide Tokunaga ; MD^r ; Shinichi Takatsuki ; MD^b ; Shinya Hara ; MD^s ; Prof Akihiro Morikawa ; MD^a ; on behalf of the RAISE study group investigators
• 刊名：The Lancet
• 出版年：2012
• 期刊代码：182_01406736
• 类别：med
• 出版时间：28 April-4 May, 2012
• 卷：379
• 期：9826
• 页码：1613-1620
• 文件大小：209 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

Evidence indicates that corticosteroid therapy might be beneficial for the primary treatment of severe Kawasaki disease. We assessed whether addition of prednisolone to intravenous immunoglobulin with aspirin would reduce the incidence of coronary artery abnormalities in patients with severe Kawasaki disease.

Methods

We did a multicentre, prospective, randomised, open-label, blinded-endpoints trial at 74 hospitals in Japan between Sept 29, 2008, and Dec 2, 2010. Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised). Patients and treating physicians were unmasked to group allocation. The primary endpoint was incidence of coronary artery abnormalities during the study period. Analysis was by intention to treat. This trial is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000000940.

Findings

We randomly assigned 125 patients to the intravenous immunoglobulin plus prednisolone group and 123 to the intravenous immunoglobulin group. Incidence of coronary artery abnormalities was significantly lower in the intravenous immunoglobulin plus prednisolone group than in the intravenous immunoglobulin group during the study period (four patients [3%] vs 28 patients [23%]; risk difference 0路20, 95%CI 0路12-0路28, p<0路0001). Serious adverse events were similar between both groups: two patients had high total cholesterol and one neutropenia in the intravenous immunoglobulin plus prednisolone group, and one had high total cholesterol and another non-occlusive thrombus in the intravenous immunoglobulin group.

Interpretation

Addition of prednisolone to the standard regimen of intravenous immunoglobulin improves coronary artery outcomes in patients with severe Kawasaki disease in Japan. Further study of intensified primary treatment for this disease in a mixed ethnic population is warranted.

Funding

Japanese Ministry of Health, Labour and Welfare.